O
VRDN icon

OppenheimerFunds’s Viridian Therapeutics VRDN Stock Holding History

OppenheimerFunds’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$88K Buy
2,110
+141
+7% +$6.38K ﹤0.01% 1740
2018
Q4 		$90K Buy
1,969
+609
+45% +$35.2K ﹤0.01% 1780
2018
Q3 		$114K Buy
+1,360
New +$128K ﹤0.01% 1802

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OppenheimerFunds's VRDN Position: Q1 2019 in Review

OppenheimerFunds increased its Viridian Therapeutics (VRDN) stake by 7.2% in Q1 2019, buying an estimated $6.38K and bringing the position to 2,110 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #1740.

OppenheimerFunds first reported a position in VRDN in Q3 2018 and has held it in 3 quarters since. The position peaked at $114K in Q3 2018. 51 funds tracked by Wall St. Rank hold VRDN as of Q1 2019.

  • OppenheimerFunds held 2,110 shares of Viridian Therapeutics worth $88K as of Q1 2019.
  • OppenheimerFunds bought 141 Viridian Therapeutics shares in Q1 2019, an estimated $6.38K.
  • Viridian Therapeutics made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1740 holding.
  • OppenheimerFunds first reported a position in Viridian Therapeutics in Q3 2018 and has held it in 3 quarters since.
  • OppenheimerFunds's Viridian Therapeutics position peaked at $114K in Q3 2018.
  • 51 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.